Lyell Immunopharma (LYEL) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Pyxis Oncology (PYXS) has outperformed Lyell Immunopharma (LYEL) over the past year, losing 50.0% versus a loss of 50.8%. Over five years, PYXS leads with a -87.1% price change compared with -97.1% for LYEL. Pyxis Oncology is the larger company by market cap ($200.7 million vs $199.0 million), about 1.0 times the size.
Pyxis Oncology converts more of its revenue into profit, with a net margin of -574.5% versus -762355.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LYEL | PYXS |
|---|---|---|
| Share price | $8.12 | $1.68 |
| Market cap | $198.98M | $200.69M |
| 1-day change | -0.85% | -6.67% |
| YTD return | -73.62% | +46.09% |
| 1-year return | -50.79% | -50.00% |
| 5-year return | -97.06% | -87.11% |
| EPS (TTM) | $-12.86 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $36.00K | $13.86M |
| Revenue growth (YoY) | -40.98% | -14.17% |
| Net income (latest FY) | $-274.45M | $-79.62M |
| Gross margin | — | 82.77% |
| Operating margin | -748344.44% | -609.18% |
| Net margin | -762355.56% | -574.55% |
| 52-week high | $45.00 | $5.55 |
| 52-week low | $7.20 | $1.03 |
| Distance from 52-week high | -81.96% | -69.73% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +366.50% | +416.07% |
| Average volume | 152.61K | 1.27M |
| Shares outstanding | 24.51M | 119.46M |
| Employees | 161 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pyxis Oncology is more profitable, keeping -574.5 cents of every revenue dollar as net income versus -762355.6 cents for Lyell Immunopharma.
- Pyxis Oncology grew revenue faster in its latest fiscal year (-14.17% vs -40.98%).
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
LYEL vs PYXS FAQ
Which is bigger, Lyell Immunopharma or Pyxis Oncology?
Pyxis Oncology (PYXS) is larger, with a market capitalization of $200.69M compared with $198.98M for Lyell Immunopharma (LYEL).
Which stock has performed better over the past year, LYEL or PYXS?
PYXS returned -50.00% over the past 12 months, compared with -50.79% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are Lyell Immunopharma and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.